1h Free Analyst Time
The human combination vaccines market is forecast to grow by USD 7.02 billion during 2023-2028, accelerating at a CAGR of 8.69% during the forecast period. The report on the human combination vaccines market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing antiviral drug resistance, increase in pediatric population, and rise in cases of infectious diseases.
The human combination vaccines market is segmented as below:
By Type
- Inactivated vaccine
- Live attenuated vaccine
By Channel
- Hospitals
- Retailers
- Online
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the human combination vaccines market covers the following areas:
- Human combination vaccines market sizing
- Human combination vaccines market forecast
- Human combination vaccines market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global human combination vaccines market: Abbott Laboratories, Arabio, Bharat Biotech., Zydus Lifesciences Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc, Grifols SA, LG Corp., Meiji Holdings Co. Ltd., Merck and Co. Inc., Mitsubishi Chemical Group Corp., Panacea Biotec Ltd., Pfizer Inc., PT Bio Farma, Sanofi SA, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Co. Ltd., Walvax Biotechnology Co. Ltd., and Biological E. Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is threat from bioterrorism."
According to the report, one of the major drivers for this market is the increasing antiviral drug resistance.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Arabio
- Bharat Biotech.
- Zydus Lifesciences Ltd.
- CSL Ltd.
- Daiichi Sankyo Co. Ltd.
- GlaxoSmithKline Plc
- Grifols SA
- LG Corp.
- Meiji Holdings Co. Ltd.
- Merck and Co. Inc.
- Mitsubishi Chemical Group Corp.
- Panacea Biotec Ltd.
- Pfizer Inc.
- PT Bio Farma
- Sanofi SA
- Serum Institute of India Pvt. Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Walvax Biotechnology Co. Ltd.
- Biological E. Ltd.
